Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LifeMD, Inc. stock logo
LFMD
LifeMD
$6.09
+0.5%
$5.46
$3.99
$12.88
$270.18M2.22815,223 shs420,752 shs
Personalis, Inc. stock logo
PSNL
Personalis
$3.84
+0.3%
$3.73
$1.14
$7.20
$339.10M1.89976,143 shs366,554 shs
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$7.07
+1.3%
$7.23
$6.21
$9.81
$279.42M1.64139,293 shs197,047 shs
Exagen Inc. stock logo
XGN
Exagen
$6.21
+6.2%
$3.98
$1.32
$6.23
$104.70M1.4689,256 shs137,223 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LifeMD, Inc. stock logo
LFMD
LifeMD
0.00%+12.15%+8.75%+18.71%-45.43%
Personalis, Inc. stock logo
PSNL
Personalis
0.00%+20.38%+7.26%-37.25%+195.38%
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
0.00%+6.64%-2.48%-16.63%-12.61%
Exagen Inc. stock logo
XGN
Exagen
0.00%+38.31%+46.46%+55.25%+353.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LifeMD, Inc. stock logo
LFMD
LifeMD
2.6803 of 5 stars
3.53.00.00.03.01.70.6
Personalis, Inc. stock logo
PSNL
Personalis
4.0283 of 5 stars
3.51.00.04.23.42.50.6
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
1.4627 of 5 stars
0.05.00.00.02.72.50.0
Exagen Inc. stock logo
XGN
Exagen
3.9906 of 5 stars
2.53.00.04.53.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$11.0080.62% Upside
Personalis, Inc. stock logo
PSNL
Personalis
3.00
Buy$7.80103.13% Upside
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
4.00
Strong BuyN/AN/A
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$7.5020.77% Upside

Current Analyst Ratings Breakdown

Latest XGN, PSNL, VMD, and LFMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
Personalis, Inc. stock logo
PSNL
Personalis
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/17/2025
Personalis, Inc. stock logo
PSNL
Personalis
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
3/12/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $14.00
3/12/2025
Exagen Inc. stock logo
XGN
Exagen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$15.00 ➝ $15.00
2/28/2025
Personalis, Inc. stock logo
PSNL
Personalis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
2/28/2025
Personalis, Inc. stock logo
PSNL
Personalis
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.25 ➝ $7.00
1/27/2025
Personalis, Inc. stock logo
PSNL
Personalis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $8.00
(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LifeMD, Inc. stock logo
LFMD
LifeMD
$212.45M1.28N/AN/A$0.15 per share40.60
Personalis, Inc. stock logo
PSNL
Personalis
$84.61M4.01N/AN/A$2.64 per share1.45
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$224.26M1.25$0.74 per share9.56$2.96 per share2.39
Exagen Inc. stock logo
XGN
Exagen
$55.64M2.00N/AN/A$1.33 per share4.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LifeMD, Inc. stock logo
LFMD
LifeMD
-$20.60M-$0.54N/A50.75N/A-12.06%N/A-36.34%5/6/2025 (Estimated)
Personalis, Inc. stock logo
PSNL
Personalis
-$108.30M-$1.37N/AN/AN/A-104.52%-66.07%-41.34%5/6/2025 (Estimated)
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$10.24M$0.2826.19N/A4.87%8.72%6.48%5/7/2025 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$23.69M-$0.83N/AN/AN/A-30.36%-92.58%-33.74%5/12/2025 (Estimated)

Latest XGN, PSNL, VMD, and LFMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04N/AN/AN/AN/AN/A
5/12/2025Q1 2025
Exagen Inc. stock logo
XGN
Exagen
-$0.20N/AN/AN/A$14.55 millionN/A
5/6/2025Q1 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23N/AN/AN/A$17.41 millionN/A
3/10/2025Q4 2024
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04-$0.02+$0.02-$0.02$57.43 million$64.26 million
2/27/2025Q4 2024
Personalis, Inc. stock logo
PSNL
Personalis
-$0.32-$0.23+$0.09-$0.23$15.48 million$16.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
0.83
0.78
Personalis, Inc. stock logo
PSNL
Personalis
N/A
4.68
4.44
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
0.03
1.31
1.19
Exagen Inc. stock logo
XGN
Exagen
1.54
4.05
4.05

Institutional Ownership

CompanyInstitutional Ownership
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
74.24%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
LifeMD, Inc. stock logo
LFMD
LifeMD
15.97%
Personalis, Inc. stock logo
PSNL
Personalis
3.80%
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
20.00%
Exagen Inc. stock logo
XGN
Exagen
26.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23044.58 million36.40 millionOptionable
Personalis, Inc. stock logo
PSNL
Personalis
40088.31 million67.75 millionOptionable
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
63039.52 million31.15 millionNot Optionable
Exagen Inc. stock logo
XGN
Exagen
22017.90 million13.03 millionOptionable

Recent News About These Companies

Exagen Inc. stock logo
Exagen Inc. (NASDAQ:XGN) Short Interest Update
Exagen Full Year 2024 Earnings: EPS Beats Expectations
Exagen (XGN) Gets a Buy from Canaccord Genuity
Exagen reports Q4 EPS (20c), consensus (24c)
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

LifeMD stock logo

LifeMD NASDAQ:LFMD

$6.09 +0.03 (+0.50%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$5.88 -0.21 (-3.37%)
As of 04/25/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Personalis stock logo

Personalis NASDAQ:PSNL

$3.84 +0.01 (+0.26%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$3.84 0.00 (-0.13%)
As of 04/25/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Viemed Healthcare stock logo

Viemed Healthcare NASDAQ:VMD

$7.07 +0.09 (+1.29%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$7.07 0.00 (0.00%)
As of 04/25/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

Exagen stock logo

Exagen NASDAQ:XGN

$6.21 +0.36 (+6.15%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$6.00 -0.22 (-3.46%)
As of 04/25/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.